Astrazeneca Ab

Nps Allelix Corporation

Allelix Biopharmaceuticals Inc.

Mindset Pharma Inc.

Nps Pharmaceuticals, Inc.

Trillium Therapeutics Inc.

Nps Allelix Biopharmaceuticals, Inc.

Abdelmalik Slassi

Methvin Benjamin Isaac

Louise G Edwards

Tao Xin

Ashok Tehim

Ian Egle

Fupeng Ma

Joshua Clayton

Jalaj Arora

James Empfield

Joseph Araujo

Tomislav Stefanac

David Wensbo

Donald A McLeod

Bradford C Van Wagenen

Sumanas Rakhit

Anne O'Brien

Thomas M Stormann

Rebecca Urbanek

Gary Steelman

Peter Dove

Alexander Minidis

Radhakrishnan Ukkiramapandian

Sally Walsh

Martin Johansson

Annika Kers

James Jeffrey Folmer

Babu Joseph

Karin Staaf

Qingchang Meng

Scott T Moe

Shawn Maddaford

Daryl Lynn Smith

Susan M Sheehan

Guy A Higgins

Methvin Issac

Dean Brown

Kenneth Lars Granberg

Andreas Christer Wallberg

Krzysztof Swierczek

Ulrika Yngve

Helena Gyback

Erwan Arzel

Qi Qiao

Karolina Nilsson

Björn Holm

Mats Nagard

Johan Malmberg

Alexander Mindis

Tau Xin

Tom Stefanac

Don McLeod

Caroline Eriksson

Veronica Profir

Per-Olov Bergstrom

John Malmberg

Karin Oscarsson

Mangus Waldman

Christoffer Osterwall

William Michne

Oingchang Meng

Bradford Van Wagenen

Donald Mcleod

Thomas Stormann

The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.

Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders

The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.

3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders

The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. 

The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions. 

A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other disorders related mediated by Bromodomain-Containing Proteins. 

Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins

The present application relates to novel fluorinated amide derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and memory deficits, as well as chronic and acute pain and other related CNS disorders. 

Fluorinated amide derivatives and their uses as therapeutic agents

The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and/or memory deficits, as well as chronic and acute pain and other related CNS disorders. 

Heterocycle derivatives and their use for the treatment of CNS disorders

A novel class of fluorinated derivatives of Formula (I) have been prepared and found to be useful in the treatment of cancers and other disorders related mediated by Bromodomain-Containing Proteins. 

The present application relates to novel fluorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application includes compounds of Formula I, and compositions and uses thereof. 

Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors

Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias. wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R; Ris chosen from: alkyl or haloalkyl; Ris chosen from: H, C(O)R, C(O)OR, SO2Ror C(O)NRR; R, Rand Rare independently chosen from: H or alkyl; Rand Rare independently chosen from: H or alkyl; and Ris chosen from: OH, CN, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, C(O)R, C(O)OR, SO2Ror C(O)NRR. 

Use of D-serine derivatives for the treatment of anxiety disorders

Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842

Compounds of Formula (I) wherein Rand Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same. 

Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators&#x2014;842

Growing community of inventors

Mississauga, Canada

Abdelmalik Slassi